University of Lodz, Faculty of Environmental Protection, Laboratory of Medical Genetics, Lodz, Poland.
Department of Medical Biochemistry, Medical University of Lodz, Lodz, Poland.
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Dec 20;95:109678. doi: 10.1016/j.pnpbp.2019.109678. Epub 2019 Jun 22.
MDDs (major depressive disorders) belong to the most frequently diagnosed mental diseases and affect approximately 350 million people all over the world. A growing body of evidence suggests that inflammatory processes may play a significant role in the pathophysiology and progression of the disease. The comorbidity of MDDs with many other medical conditions, for example autoimmune diseases (ADs) caused by inflammation, has been observed on numerous occasions. In both cases, increased levels of pro-inflammatory cytokines, chemokines and other inflammatory agents are observed. Furthermore, higher rates of inflammatory markers are associated with a poorer response to antidepressant treatment. Additionally, the presence of any AD is associated with higher prevalence of depression and may reduce the chance of effective therapy. Interestingly, the administration of several anti-inflammatory agents used in AD treatment is positively correlated with a reduction of depressive symptoms. In conclusion, the factors contributing to the coexistence of depression as well as affecting antidepressant treatment effectiveness may lead to an alteration of the cytokine profiles in many autoimmune diseases.
MDD（重度抑郁症）属于最常见的精神疾病之一，全球约有 3.5 亿人受其影响。越来越多的证据表明，炎症过程可能在疾病的病理生理学和进展中起重要作用。MDD 与许多其他医学疾病（如由炎症引起的自身免疫性疾病 (AD)）的合并症已多次被观察到。在这两种情况下，都观察到促炎细胞因子、趋化因子和其他炎症介质水平升高。此外，更高的炎症标志物水平与对抗抑郁治疗的反应较差有关。此外，任何 AD 的存在都与更高的抑郁患病率相关，并可能降低有效治疗的机会。有趣的是，几种用于 AD 治疗的抗炎药物的给药与抑郁症状的减轻呈正相关。总之，导致抑郁共存以及影响抗抑郁治疗效果的因素可能导致许多自身免疫性疾病细胞因子谱发生变化。
